US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Artiva Biotherapeutics, Inc.

10.32

-0.9800-8.67%

Post-market: 10.21-0.1100-1.07%18:27 EDT

Volume:153.17K

Turnover:1.65M

Market Cap:255.08M

PE:-3.01

High:11.64

Open:11.42

Low:10.23

Close:11.30

52wk High:14.53

52wk Low:1.47

Shares:24.72M

Float Shares:5.38M

Volume Ratio:0.31

T/O Rate:2.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4309

EPS(LYR):-3.4309

ROE:-56.55%

ROA:-32.97%

PB:2.32

PE(LYR):-3.01

Loading ...

Overview Company News Filings

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies

Artiva Biotherapeutics Price Target Maintained With a $18.00/Share by Needham

Artiva Biotherapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate

Artiva Biotherapeutics FY2025 net loss rises 28% to USD 83.87 million

Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Files Initial Beneficial Ownership Statement for CFO Huston Thad Allen

Artiva Biotherapeutics Awards CFO Thad Huston 220,000 RSUs Under 2025 Inducement Plan

Press Release: Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Artiva Biotherapeutics Names Elaine Sorg to Board of Directors

Artiva (ARTV): Off‑the‑Shelf AlloNK Platform Positions Lead RA Program for Pivotal De‑Risking and Attractive Risk‑Reward

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)

Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data

Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares

US Stocks Mixed; NY Manufacturing Activity Dips In December

Artiva Biotherapeutics Replaces Underwater Stock Options with RSUs for Key Executives

Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares

Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development

Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases

Artiva Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARTV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARTV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":10.32,"timestamp":1777060800000,"preClose":11.3,"halted":0,"volume":153173,"hourTrading":{"tag":"盘后","latestPrice":10.21,"preClose":10.32,"latestTime":"18:27 EDT","volume":1687,"amount":17308.7142,"timestamp":1777069641310,"change":-0.11,"changeRate":-0.010659,"amplitude":0.015504},"delay":0,"changeRate":-0.08672566371681419,"floatShares":5381708,"shares":24716672,"eps":-3.430895,"marketStatus":"Market Closed","change":-0.98,"latestTime":"04-24 16:00:00 EDT","open":11.42,"high":11.635,"low":10.23,"amount":1645619.9460739999,"amplitude":0.124336,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.430895,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":11.3,"preHourTrading":{"tag":"盘前","latestPrice":11.83,"preClose":11.3,"latestTime":"08:56 EDT","volume":2503,"amount":29374.484633,"timestamp":1777035408723,"change":0.53,"changeRate":0.046903,"amplitude":0.024779},"postHourTrading":{"tag":"盘后","latestPrice":10.21,"preClose":10.32,"latestTime":"18:27 EDT","volume":1687,"amount":17308.7142,"timestamp":1777069641310,"change":-0.11,"changeRate":-0.010659,"amplitude":0.015504},"volumeRatio":0.308467134557406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","floatShares":5381708,"roa":"-32.97%","roe":"-56.55%","lyrEps":-3.430895,"volumeRatio":0.308467134557406,"shares":24716672,"dividePrice":0,"high":11.635,"amplitude":0.124336,"preClose":11.3,"low":10.23,"week52Low":1.47,"pbRate":"2.32","week52High":14.53,"institutionHeld":0,"latestPrice":10.32,"eps":-3.430895,"divideRate":0,"volume":153173,"delay":0,"ttmEps":-3.430895,"open":11.42,"prevYearClose":4.29,"prevWeekClose":12.55,"prevMonthClose":6.44,"prevQuarterClose":6.44,"fiveDayClose":12.55,"twentyDayClose":5.16,"sixtyDayClose":4.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARTV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-10","symbol":"ARTV","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-11-12","symbol":"ARTV","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.88},{"market":"US","date":"2025-08-06","symbol":"ARTV","fiscalQuarterEnding":"2025/06","expectedEps":-0.84,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.87},{"market":"US","date":"2025-05-08","symbol":"ARTV","fiscalQuarterEnding":"2025/03","expectedEps":-0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.83}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARTV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARTV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARTV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARTV","date":"2026-04-24","current":-3.007961,"percent":0.269142,"low":-11.820615,"twenty":-4.432458,"median":-1.470747,"eighty":-0.907501,"high":-0.499349,"avg":-2.93515,"sd":3.119887,"marketCap":279298393},"quantilePoints":[{"date":"2024-08-02","current":-10.391793,"twenty":-10.391793,"median":-10.391793,"eighty":-10.391793,"marketCap":269833291},{"date":"2024-08-09","current":-9.862789,"twenty":-10.391793,"median":-10.042112,"eighty":-9.943484,"marketCap":256097171},{"date":"2024-08-16","current":-10.185571,"twenty":-10.248334,"median":-10.131774,"eighty":-9.95245,"marketCap":264478532},{"date":"2024-08-23","current":-8.939273,"twenty":-10.248334,"median":-10.051078,"eighty":-9.342751,"marketCap":232117163},{"date":"2024-08-30","current":-8.088598,"twenty":-10.185571,"median":-9.943484,"eighty":-9.046867,"marketCap":263081639},{"date":"2024-09-06","current":-8.893463,"twenty":-10.142533,"median":-9.800025,"eighty":-8.930111,"marketCap":289259885},{"date":"2024-09-13","current":-8.019798,"twenty":-10.131774,"median":-9.459311,"eighty":-8.763533,"marketCap":260843926},{"date":"2024-09-20","current":-8.759053,"twenty":-10.07439,"median":-9.028935,"eighty":-8.450238,"marketCap":284888199},{"date":"2024-09-27","current":-9.946342,"twenty":-10.07439,"median":-9.323455,"eighty":-8.581333,"marketCap":323504758},{"date":"2024-10-04","current":-11.499524,"twenty":-10.277026,"median":-9.57298,"eighty":-8.727691,"marketCap":374022017},{"date":"2024-10-11","current":-10.566121,"twenty":-10.505561,"median":-9.728296,"eighty":-8.794895,"marketCap":343663087},{"date":"2024-10-18","current":-9.543111,"twenty":-10.587029,"median":-9.800025,"eighty":-8.869568,"marketCap":310389700},{"date":"2024-10-25","current":-7.586699,"twenty":-10.505561,"median":-9.574426,"eighty":-8.581333,"marketCap":246757383},{"date":"2024-10-31","current":-7.579232,"twenty":-10.485041,"median":-9.464706,"eighty":-8.226879,"marketCap":246514511},{"date":"2024-11-08","current":-10.424244,"twenty":-10.485041,"median":-9.3863,"eighty":-8.226879,"marketCap":339048530},{"date":"2024-11-15","current":-4.166082,"twenty":-10.46953,"median":-9.378833,"eighty":-8.149728,"marketCap":255280837},{"date":"2024-11-22","current":-4.310765,"twenty":-10.439178,"median":-9.30416,"eighty":-7.969021,"marketCap":264146442},{"date":"2024-11-29","current":-5.065892,"twenty":-10.411264,"median":-9.046867,"eighty":-7.81669,"marketCap":310417611},{"date":"2024-12-06","current":-4.598149,"twenty":-10.334409,"median":-8.970887,"eighty":-7.365669,"marketCap":281756204},{"date":"2024-12-13","current":-4.233469,"twenty":-10.223229,"median":-8.939273,"eighty":-5.058757,"marketCap":259410023},{"date":"2024-12-20","current":-3.963922,"twenty":-10.173512,"median":-8.885996,"eighty":-4.852633,"marketCap":242893280},{"date":"2024-12-27","current":-4.17401,"twenty":-10.150694,"median":-8.781454,"eighty":-4.667914,"marketCap":255766623},{"date":"2025-01-03","current":-3.95203,"twenty":-10.131774,"median":-8.549971,"eighty":-4.598149,"marketCap":242164600},{"date":"2025-01-10","current":-4.066984,"twenty":-10.131774,"median":-8.396892,"eighty":-4.398368,"marketCap":249208505},{"date":"2025-01-17","current":-2.687539,"twenty":-10.07439,"median":-8.17661,"eighty":-4.337719,"marketCap":164681643},{"date":"2025-01-24","current":-2.477451,"twenty":-10.049285,"median":-8.109405,"eighty":-4.224748,"marketCap":151808300},{"date":"2025-01-31","current":-2.140518,"twenty":-10.011532,"median":-8.012331,"eighty":-4.193829,"marketCap":131162371},{"date":"2025-02-07","current":-1.823404,"twenty":-9.967928,"median":-7.881014,"eighty":-4.108209,"marketCap":111730908},{"date":"2025-02-14","current":-1.589533,"twenty":-9.948785,"median":-7.698708,"eighty":-3.978192,"marketCap":97400205},{"date":"2025-02-21","current":-1.502326,"twenty":-9.945199,"median":-7.508293,"eighty":-3.804572,"marketCap":92056553},{"date":"2025-02-28","current":-1.478543,"twenty":-9.911206,"median":-5.18038,"eighty":-2.77871,"marketCap":90599193},{"date":"2025-03-07","current":-2.0216,"twenty":-9.837683,"median":-5.059946,"eighty":-2.521847,"marketCap":123875572},{"date":"2025-03-14","current":-2.219796,"twenty":-9.795827,"median":-4.998506,"eighty":-2.343471,"marketCap":136020236},{"date":"2025-03-21","current":-1.601424,"twenty":-9.736345,"median":-4.76067,"eighty":-2.165887,"marketCap":98128885},{"date":"2025-03-28","current":-1.319282,"twenty":-9.624289,"median":-4.665536,"eighty":-2.054897,"marketCap":86245441},{"date":"2025-04-04","current":-0.946604,"twenty":-9.574715,"median":-4.606077,"eighty":-1.965312,"marketCap":61882322},{"date":"2025-04-11","current":-0.685729,"twenty":-9.561032,"median":-4.439593,"eighty":-1.797242,"marketCap":44828138},{"date":"2025-04-17","current":-0.857161,"twenty":-9.511749,"median":-4.37617,"eighty":-1.744126,"marketCap":56035173},{"date":"2025-04-25","current":-0.913063,"twenty":-9.383313,"median":-4.344458,"eighty":-1.606181,"marketCap":59689641},{"date":"2025-05-02","current":-0.883248,"twenty":-9.365642,"median":-4.233469,"eighty":-1.560992,"marketCap":57740592},{"date":"2025-05-09","current":-0.740531,"twenty":-9.335033,"median":-4.213649,"eighty":-1.495984,"marketCap":53111599},{"date":"2025-05-16","current":-0.723546,"twenty":-9.26085,"median":-4.193829,"eighty":-1.480232,"marketCap":51893443},{"date":"2025-05-23","current":-0.672592,"twenty":-9.079462,"median":-4.170046,"eighty":-1.376675,"marketCap":48238975},{"date":"2025-05-30","current":-0.696371,"twenty":-9.046867,"median":-4.104641,"eighty":-1.177664,"marketCap":49944393},{"date":"2025-06-06","current":-0.665798,"twenty":-9.028935,"median":-3.995633,"eighty":-0.946604,"marketCap":47751713},{"date":"2025-06-13","current":-0.696371,"twenty":-8.975602,"median":-3.957976,"eighty":-0.913063,"marketCap":49944393},{"date":"2025-06-20","current":-0.570684,"twenty":-8.968058,"median":-3.829149,"eighty":-0.909336,"marketCap":40930039},{"date":"2025-06-27","current":-0.533318,"twenty":-8.961769,"median":-2.822312,"eighty":-0.881757,"marketCap":38250096},{"date":"2025-07-03","current":-0.546906,"twenty":-8.947831,"median":-2.762854,"eighty":-0.830328,"marketCap":39224621},{"date":"2025-07-11","current":-0.60805,"twenty":-8.911787,"median":-2.592405,"eighty":-0.73948,"marketCap":43609983},{"date":"2025-07-18","current":-0.879805,"twenty":-8.888983,"median":-2.477451,"eighty":-0.736237,"marketCap":63100478},{"date":"2025-07-25","current":-1.168544,"twenty":-8.885996,"median":-2.34466,"eighty":-0.73948,"marketCap":83809129},{"date":"2025-08-01","current":-1.019079,"twenty":-8.836712,"median":-2.219796,"eighty":-0.740531,"marketCap":73089357},{"date":"2025-08-08","current":-0.856075,"twenty":-8.776974,"median":-2.136554,"eighty":-0.74119,"marketCap":64318634},{"date":"2025-08-15","current":-0.877783,"twenty":-8.664966,"median":-2.104843,"eighty":-0.766227,"marketCap":65949557},{"date":"2025-08-22","current":-0.90054,"twenty":-8.539516,"median":-2.017636,"eighty":-0.794855,"marketCap":67659360},{"date":"2025-08-29","current":-1.027331,"twenty":-8.461857,"median":-1.938358,"eighty":-0.806285,"marketCap":77185407},{"date":"2025-09-05","current":-1.011075,"twenty":-8.405106,"median":-1.906646,"eighty":-0.809828,"marketCap":75964119},{"date":"2025-09-12","current":-0.864778,"twenty":-8.31765,"median":-1.769891,"eighty":-0.816568,"marketCap":64972526},{"date":"2025-09-19","current":-0.773749,"twenty":-8.226879,"median":-1.740162,"eighty":-0.790778,"marketCap":58133313},{"date":"2025-09-26","current":-0.978565,"twenty":-8.17661,"median":-1.635118,"eighty":-0.805192,"marketCap":73521543},{"date":"2025-10-03","current":-0.959059,"twenty":-8.149728,"median":-1.601424,"eighty":-0.809828,"marketCap":72055997},{"date":"2025-10-10","current":-0.975314,"twenty":-8.101082,"median":-1.571695,"eighty":-0.816568,"marketCap":73277286},{"date":"2025-10-17","current":-0.90054,"twenty":-8.061078,"median":-1.530074,"eighty":-0.825779,"marketCap":67659360},{"date":"2025-10-24","current":-1.573506,"twenty":-8.013824,"median":-1.539983,"eighty":-0.830317,"marketCap":118220688},{"date":"2025-10-31","current":-1.280912,"twenty":-7.969021,"median":-1.537745,"eighty":-0.833281,"marketCap":96237502},{"date":"2025-11-07","current":-1.11836,"twenty":-7.90156,"median":-1.498363,"eighty":-0.837688,"marketCap":84024621},{"date":"2025-11-14","current":-1.102105,"twenty":-7.858868,"median":-1.490435,"eighty":-0.847643,"marketCap":82803333},{"date":"2025-11-21","current":-0.982565,"twenty":-7.819676,"median":-1.476561,"eighty":-0.856509,"marketCap":77807345},{"date":"2025-11-28","current":-1.16544,"twenty":-7.765913,"median":-1.457948,"eighty":-0.858684,"marketCap":92288839},{"date":"2025-12-05","current":-1.170089,"twenty":-7.585206,"median":-1.427209,"eighty":-0.865066,"marketCap":92657012},{"date":"2025-12-12","current":-0.973266,"twenty":-7.550856,"median":-1.356118,"eighty":-0.866579,"marketCap":77070998},{"date":"2025-12-19","current":-1.441302,"twenty":-7.413459,"median":-1.35655,"eighty":-0.869582,"marketCap":114133803},{"date":"2025-12-26","current":-1.332817,"twenty":-7.317879,"median":-1.35655,"eighty":-0.875795,"marketCap":105543087},{"date":"2026-01-02","current":-1.329717,"twenty":-5.60788,"median":-1.355686,"eighty":-0.876285,"marketCap":105297638},{"date":"2026-01-09","current":-1.419605,"twenty":-5.08879,"median":-1.356118,"eighty":-0.877508,"marketCap":112415660},{"date":"2026-01-16","current":-1.38241,"twenty":-5.065892,"median":-1.373111,"eighty":-0.877783,"marketCap":109470271},{"date":"2026-01-23","current":-1.534289,"twenty":-5.058757,"median":-1.38241,"eighty":-0.877783,"marketCap":121497274},{"date":"2026-01-30","current":-1.286323,"twenty":-5.046865,"median":-1.38396,"eighty":-0.878996,"marketCap":101861351},{"date":"2026-02-06","current":-1.199535,"twenty":-5.015947,"median":-1.373111,"eighty":-0.880542,"marketCap":94988778},{"date":"2026-02-13","current":-1.23673,"twenty":-4.922398,"median":-1.361731,"eighty":-0.882362,"marketCap":97934166},{"date":"2026-02-20","current":-1.404107,"twenty":-4.858976,"median":-1.356118,"eighty":-0.88623,"marketCap":111188415},{"date":"2026-02-27","current":-1.689268,"twenty":-4.776526,"median":-1.370012,"eighty":-0.890736,"marketCap":133769726},{"date":"2026-03-06","current":-1.779155,"twenty":-4.679806,"median":-1.38241,"eighty":-0.892087,"marketCap":140887748},{"date":"2026-03-13","current":-1.989358,"twenty":-4.672671,"median":-1.404107,"eighty":-0.894194,"marketCap":166837536},{"date":"2026-03-20","current":-1.626853,"twenty":-4.654437,"median":-1.418531,"eighty":-0.895573,"marketCap":136436029},{"date":"2026-03-27","current":-1.520754,"twenty":-4.628275,"median":-1.425804,"eighty":-0.898589,"marketCap":127538027},{"date":"2026-04-02","current":-1.989358,"twenty":-4.610834,"median":-1.432003,"eighty":-0.90054,"marketCap":166837536},{"date":"2026-04-10","current":-2.004094,"twenty":-4.574366,"median":-1.4506,"eighty":-0.90119,"marketCap":168073369},{"date":"2026-04-17","current":-3.569056,"twenty":-4.471304,"median":-1.457173,"eighty":-0.904441,"marketCap":299318897},{"date":"2026-04-24","current":-3.330333,"twenty":-4.432458,"median":-1.470747,"eighty":-0.907501,"marketCap":279298393}],"updateTime":1777115485471},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARTV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625491949","title":"Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2625491949","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625491949?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270027/0/en/Artiva-Biotherapeutics-to-Participate-in-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV","BK4588","LABU","XBI","LU0128526141.USD","BK4585","BK4581","HCSG","BK4137","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618513207","title":"Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2618513207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618513207?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:20","pubTimestamp":1773321609,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Artiva Biotherapeutics, Inc. today and set a price target of $19.00. In addition to Jefferies, Artiva ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/artiva-biotherapeutics-inc-artv-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/artiva-biotherapeutics-inc-artv-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618949683","title":"Artiva Biotherapeutics Price Target Maintained With a $18.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2618949683","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618949683?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:59","pubTimestamp":1773226740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 06:59 ET (10:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618969883","title":"Artiva Biotherapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618969883","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618969883?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:10","pubTimestamp":1773173429,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.45 percent. This is a 27.27 percent decrease over losses of $(0.66) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51173483/artiva-biotherapeutics-q4-eps-0-84-misses-0-83-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Artiva Biotherapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618966229","title":"Artiva Biotherapeutics FY2025 net loss rises 28% to USD 83.87 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966229","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966229?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:07","pubTimestamp":1773173240,"startTime":"0","endTime":"0","summary":"Artiva reported a FY 2025 net loss of USD 83.87 million, widening 28% from the prior year. FY 2025 research and development expenses rose 38% to USD 69.54 million, while general and administrative expenses increased 18% to USD 20.27 million. Other income, net was USD 5.95 million in FY 2025, up more than doubled from the prior year. Artiva ended FY 2025 with cash, cash equivalents and investments of USD 108.01 million, which it expects will fund operations into Q2 2027. Management said initial clinical response data for AlloNK in refractory rheumatoid arthritis are expected in H1 2026, alongside an FDA interaction on a potential pivotal trial design.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL51xkqZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","SG9999014021.USD","SG9999014039.USD","ARTV","BK4139","SG9999014005.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618966465","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966465","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966465?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:05","pubTimestamp":1773173100,"startTime":"0","endTime":"0","summary":"Initial clinical response data for AlloNK in refractory rheumatoid arthritis  expected in first half of 2026. U.S. Food and Drug Administration  interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026. Strengthened board and executive leadership with deep immunology, commercial and financial expertise. Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027. Dr. Aslan continued, \"In 2026, our focus is to advance AlloNK from an early clinical program in the deep B-cell depletion space to what could become the first therapy in this class to initiate a registrational trial in RA, the autoimmune disease with the largest refractory population. We look forward to sharing initial clinical response data and engaging with the FDA on a potential pivotal trial design in refractory RA in the first half of 2026.\". -- Prioritized refractory RA as lead indication: Recei","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","SLE","BK4139","BK4006","IE0031619046.USD","IE00B19Z4B17.USD","RA","IE00B7SZL793.SGD","R","LU2065731478.USD","IE00B66KJ199.SGD","BK4077","BK4022","BK4187","LU0963586101.USD","ARTV","CRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614726617","title":"Artiva Biotherapeutics Files Initial Beneficial Ownership Statement for CFO Huston Thad Allen","url":"https://stock-news.laohu8.com/highlight/detail?id=2614726617","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614726617?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:16","pubTimestamp":1771971384,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics, Inc. filed an initial statement of beneficial ownership naming Huston Thad Allen, Chief Financial Officer, as the reporting person. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL65phgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Artiva Biotherapeutics Files Initial Beneficial Ownership Statement for CFO Huston Thad Allen","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613371117","title":"Artiva Biotherapeutics Awards CFO Thad Huston 220,000 RSUs Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2613371117","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613371117?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:03","pubTimestamp":1771938220,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics said its board approved an employment inducement grant for newly appointed CFO Thad Huston consisting of 220,000 restricted stock units under the company’s 2025 Inducement Plan. The award is expected to be granted after an S-8 registration statement is filed, and will vest over four years, with 25% vesting on Feb. 15, 2027 and the remainder vesting quarterly thereafter, subject to continued employment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3CBMZx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","ARTV","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","BK4112","SG9999014039.USD","BK4585","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613927711","title":"Press Release: Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927711","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613927711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 24, 2026  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.\"We are delighted to welcome Thad to Artiva as he brings strong late-stage development and commercial expertise to our leadership team,\" said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. \"AlloNK has the potential to deliver deep B-cell depletion with biologics-like convenience. This is an important time for Artiva as we prepare to receive feedback from the FDA on a potential pivotal trial and sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4139","ARTV","BK4232","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612407714","title":"Artiva Biotherapeutics Names Elaine Sorg to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407714","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407714?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506048,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. appointed Elaine Sorg to its Board of Directors. Sorg brings more than 35 years of biopharmaceutical leadership and commercialization experience, including senior roles at AbbVie and Eli Lilly, and has helped lead launches of immunology therapies such as Humira and Rinvoq.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL7Xnznl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2491049909.HKD","LU1244550494.USD","LU2237443978.SGD","LU0316494557.USD","LU2129689605.HKD","IE0002270589.USD","SG9999001176.USD","LU0672654240.SGD","IE00B1BXHZ80.USD","LU2456880835.USD","LU2360106947.USD","LU2089984988.USD","LU0323591593.USD","IE0004445015.USD","LU0354030438.USD","LU0256863811.USD","SG9999015986.USD","LU0158827781.USD","LU0225283273.USD","ARTV","LU2237443549.SGD","LU1057294990.SGD","LU0823416689.USD","LU2168563687.JPY","LU0417517546.SGD","LU1291159041.SGD","LU2361044949.HKD","LU1064131342.USD","LU2168564065.EUR","LU0109391861.USD","LU2210150020.SGD","IE0005OL40V9.USD","LU0708994859.HKD","LU2461242641.AUD","LU0234572021.USD","LU0553294199.USD","LU2750360997.AUD","LU1093756168.USD","LU1061106388.HKD","LU0471298777.SGD","IE00B19Z3581.USD","SG9999014005.SGD","LU2471134523.USD","LU1934455194.USD","LU0320765059.SGD","LU0385154629.USD","LU2896262040.SGD","LU0823434740.USD","LU0795875169.SGD","IE00BFSS8Q28.SGD","LU1712237335.SGD","IE00B2B36J28.USD","LU0738911758.USD","LU0289961442.SGD","LU2023251221.USD","ELIL","LU0354030511.USD","LU2471134879.HKD","LU0466842654.USD","BK4516","SGXZ99366536.SGD","LU0545039389.USD","LU1868836914.USD","IE00BKDWB100.SGD","LU0456855351.SGD","LU2756315318.SGD","IE00B3QW5Z07.USD","LU2087625088.SGD","BK4550","LU0266013472.USD","IE00B19Z3B42.SGD","IE00BVYPNW00.USD","IE00BSNM7G36.USD","IE00B4R5TH58.HKD","LU0353189763.USD","LU2023250330.USD","LU1551013342.USD","LU0965509101.SGD","LU0058720904.USD","LU0211327993.USD","LU2168564222.USD","LU0640476718.USD","LU1868837300.USD","LU1623119135.USD","LU2264538146.SGD","LU0097036916.USD","LU1868836757.USD","LU2237443382.USD","LU1934455277.USD","IE00BJJMRY28.SGD","IE0002141913.USD","LU0432979614.USD","IE0009355771.USD","LU1989772840.SGD","LU0965509283.SGD","LU1929549753.HKD","LLYZ","LU1244550577.SGD","LU2213496289.HKD","LU0061475181.USD","LU0795875086.SGD","LU0471298694.HKD","LU1839511570.USD","LU0096364046.USD","LU0094547139.USD","BK4559","SGXZ57979304.SGD","LU0203345920.USD","LU1267930490.SGD","LU2361045086.USD","GB00BDT5M118.USD","LU2108987350.USD","LU0079474960.USD","LU0006306889.USD","LU0661504455.SGD","LU2491050071.SGD","LU0985320562.USD","SG9999011175.SGD","LU0786609619.USD","BK4581","LU0069063385.USD","LU2271345857.HKD","LU0708995401.HKD","IE0004445239.USD","LU0238689110.USD","LU2237443895.HKD","SG9999014021.USD","LU1162221912.USD","LU2168564495.EUR","SG9999014914.USD","LU1732799900.SGD","LU0965509010.AUD","LU2361044865.SGD","IE00BKPKM429.USD","LU2471134952.CNY","LU2237443622.USD","LU2462157665.USD","LU1003077747.HKD","LU2095319765.USD","LU0234570918.USD","SG9999015978.USD","SGXZ51526630.SGD","LU1732800096.USD","SGXZ31699556.SGD","LU1868837136.USD","LU2028103732.USD","LU1267930573.SGD","LU0289739343.SGD","LU0689472784.USD","IE00BN29S564.USD","BK4139","IE00B42XCP33.USD","LU0122379950.USD","LU0511384066.AUD","LU0114720955.EUR","LU0820561909.HKD","LU0320765646.SGD","LU1093756325.SGD","LU0310800379.SGD","IE00B1XK9C88.USD","LU0203202063.USD","LU0861579265.USD","SG9999015945.SGD","LU0314104364.USD","BK4007","LU2237438978.USD","LU0820562030.AUD","LU1037948541.HKD","LU1868836591.USD","LU0158827948.USD","LU1585245621.USD","IE00BJLML261.HKD","LU2112291526.USD","LU2111349929.HKD","IE00B3PB1722.GBP","LU1974910355.USD","LU0128525929.USD","LU0029864427.USD","IE00BVYPNV92.GBP","BK4599","LU2106854487.HKD","LU2756315664.SGD","LU1814569148.SGD","LU2347655156.SGD","LU1127390331.HKD","LU1244550221.USD","LU0683600562.USD","LU1280957306.USD","SG9999014906.USD","LU2237443465.HKD","LU2552382058.USD","LU2552382132.HKD","LU0882574055.USD","LU0889565916.HKD","LU0203347892.USD","SG9999001176.SGD","LU2324357040.USD","LU2552382215.SGD","LU0203201768.USD","SGXZ81514606.USD","LU2357305700.SGD","LU2236285917.USD","LU2089284900.SGD","LU2491050154.USD","LU0823434583.USD","IE00BDGV0183.EUR","LU0787776722.HKD","LU0943347566.SGD","SG9999014898.SGD","LU0310799852.SGD","LU0472753341.HKD","LU1323610961.USD","LU2168564149.EUR","LU2211815571.USD","LLYX","LU0912757837.SGD","IE00BLSP4239.USD","LU1267930730.SGD","SG9999003800.SGD","IE00BFSS7M15.SGD","SG9999018857.SGD","IE00B775H168.HKD","IE00BK4W5M84.HKD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU2133065610.SGD","LU1548497426.USD","IE00BBT3K403.USD","LU0057025933.USD","LU1804176565.USD","IE00BWXC8680.SGD","BK4534","IE00BJT1NW94.SGD","SG9999014880.SGD","IE00B7KXQ091.USD","SG9999018865.SGD","LU0965508806.USD","BK4585","LU1496350502.SGD","LU2471134796.USD","LU2129689514.USD","BK4588","LU1037948897.HKD","LU1917777945.USD","LU2265009873.SGD","LU2468319806.SGD","LU1718418525.SGD","BK4533","LU1983299246.USD","LU1232071149.USD","LU0689626769.HKD","LU2089283258.USD","LU1496350171.SGD","LU1988902786.USD","IE00BLSP4452.SGD","LU1366192091.USD","LU0106261372.USD","IE00BJJMRZ35.SGD","LU2746668461.USD","SG9999013999.USD","LU0949170772.SGD","LU1934455863.HKD","LU2417539215.USD","LU0353189680.USD","LU0289739699.SGD","LU0964807845.USD","LU1069344957.HKD","LU0109394709.USD","LU2210149790.SGD","LU0124676726.USD","LU1720051017.SGD","LU1035775433.USD","LU2023250504.SGD","LU2746668974.SGD","SG9999017495.SGD","LU2063271972.USD","LU1989771016.USD","LU0098860793.USD","LU0210536198.USD","LU0882574139.USD","LU0320765992.SGD","LU1629891620.HKD","LU2087621335.USD","IE00B4JS1V06.HKD","IE00BGHQF748.EUR","IE00BJJMRX11.SGD","LU0198837287.USD","LU1430594728.SGD","LU2750360641.GBP","LU1989772923.USD","LU0256863902.USD","SG9999014013.SGD","LU0170899867.USD","IE00BFTCPJ56.SGD","SG9999014039.USD","LU2129689431.USD","LU1145028129.USD","IE00BK4W5L77.USD","SG9999015952.SGD","LU1074936037.SGD","SG9999001440.SGD","IE00B64PRP62.GBP","LU2602419157.SGD","LU1551013425.SGD","IE00BGHQF631.EUR","LU0820561818.USD","LU1720051108.HKD","LU0211328371.USD","BK4112","ELIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612106214","title":"Artiva (ARTV): Off‑the‑Shelf AlloNK Platform Positions Lead RA Program for Pivotal De‑Risking and Attractive Risk‑Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2612106214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612106214?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:37","pubTimestamp":1771414647,"startTime":"0","endTime":"0","summary":"In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $15.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-artv-off‑the‑shelf-allonk-platform-positions-lead-ra-program-for-pivotal-de‑risking-and-attractive-risk‑reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-artv-off‑the‑shelf-allonk-platform-positions-lead-ra-program-for-pivotal-de‑risking-and-attractive-risk‑reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","RA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605481145","title":"Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481145?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:40","pubTimestamp":1769013615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Artiva ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","XLV","BK4007","HCSG","BK4137","BK4139","BK4588","LU0128526141.USD","BK4581","ARTV","TRVI","LABU","XBI","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605021271","title":"Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2605021271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605021271?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000434,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. announced upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The company will present new data on the cost-effectiveness of its off-the-shelf NK cell therapy, AB-101 , in outpatient community rheumatology practices, highlighting its comparison to CAR-T treatments for rheumatologic diseases. Additionally, updated results on the continued durability of AlloNK in patients with relapsed or refractory Non-Hodgkin Lymphoma will be shared. These results will be presented as poster sessions during the conference and have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLbQJJGk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","IE00BKPKM429.USD","BK4585","BK4588","BK4112","NDAQ","SG9999014021.USD","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591719356","title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591719356","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591719356?lang=en_us&edition=fundamental","pubTime":"2025-12-16 10:20","pubTimestamp":1765851602,"startTime":"0","endTime":"0","summary":"Fred Aslan, President and CEO of Artiva Biotherapeutics Inc., reported a disposal of common shares of Artiva Biotherapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLb5JZFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591647230","title":"US Stocks Mixed; NY Manufacturing Activity Dips In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647230","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647230?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:02","pubTimestamp":1765810978,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49394249/us-stocks-mixed-ny-manufacturing-activity-dips-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","ARTV","SQQQ","BK4139","MNTS","MASK","BK4604","USAW.SI","IRBT",".IXIC","PSQ","MNQmain","QLD","BK4191","TSYW.SI","BK4585","NVIW.SI","TQQQ","BK4567","USJW.SI","BK4209","BK4187","NQmain","QID","AMCI","BK4134","IRBTQ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2591684221","title":"Artiva Biotherapeutics Replaces Underwater Stock Options with RSUs for Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684221?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:24","pubTimestamp":1765578272,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. has implemented a new equity compensation arrangement for select employees, including President and CEO Fred Aslan and COO Jennifer Bush. Under Option for RSU Exchange Agreements, eligible participants were given a one-time opportunity to exchange outstanding stock options with exercise prices above the current market value for restricted stock units  granted under the 2024 Equity Incentive Plan. As part of the exchange, Dr. Aslan surrendered options for 869,136 shares and received an equivalent number of RSUs, while Ms. Bush exchanged options for 84,877 shares for RSUs. The RSUs granted in exchange for vested options will vest in installments between August 2026 and February 2027, with full acceleration possible upon certain termination events. RSUs granted for unvested options will vest between August 2026 and February 2029, with partial acceleration in specific circumstances. The RSU grants became effective on December 12, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL69fXnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584860926","title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584860926","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584860926?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:38","pubTimestamp":1763429907,"startTime":"0","endTime":"0","summary":"Fred Aslan, President and CEO of Artiva Biotherapeutics Inc., reported a disposal of common shares of Artiva Biotherapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4DHCKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583532521","title":"Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583532521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583532521?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:42","pubTimestamp":1763008921,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q3 earnings. Here is a breakdown of the information Artiva Biotherapeutics, Inc. presente...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-increased-losses-amid-ongoing-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-increased-losses-amid-ongoing-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583258591","title":"Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258591?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:35","pubTimestamp":1762983351,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating today. Tyler Van Buren has given his Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-artiva-biotherapeutics-allonk-therapy-for-autoimmune-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-artiva-biotherapeutics-allonk-therapy-for-autoimmune-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583644304","title":"Artiva Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583644304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583644304?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:03","pubTimestamp":1762974180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 14:03 ET (19:03 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}